China Resources Pharmaceutical Group Management

Management criteria checks 3/4

China Resources Pharmaceutical Group's CEO is Xiaosong Bai, appointed in Jan 2022, has a tenure of 2.25 years. total yearly compensation is CN¥2.55M, comprised of 98% salary and 2% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth €120.24K. The average tenure of the management team and the board of directors is 2.4 years and 3.8 years respectively.

Key information

Xiaosong Bai

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentage	98.0%
CEO tenure	2.3yrs
CEO ownership	0.003%
Management average tenure	2.4yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Xiaosong Bai's remuneration changed compared to China Resources Pharmaceutical Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	CN¥4b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥3m	CN¥2m	CN¥4b

Compensation vs Market: Xiaosong's total compensation ($USD352.03K) is below average for companies of similar size in the German market ($USD2.56M).

Compensation vs Earnings: Insufficient data to compare Xiaosong's compensation with company performance.

CEO

Xiaosong Bai (52 yo)

2.3yrs

Tenure

CN¥2,550,953

Compensation

Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xiaosong Bai	CEO & Executive Director	2.3yrs	CN¥2.55m	0.0032% CN¥ 120.2k
Ran Tao	VP & Executive Director	2.6yrs	CN¥2.76m	no data
Rong Deng	CFO & Executive Director	less than a year	no data	no data
Lu Ge	Chief Information Officer & VP	10.3yrs	no data	no data
Na Tang	Chief Legal Advisor	10.1yrs	no data	no data
Kwai Cheng	Company Secretary	no data	no data	no data
Jianjun Wu	Vice President	no data	no data	no data
Kai Qiu	Vice President of CR Pharma & Chairman of China Resources Boya	no data	no data	no data

2.4yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 640's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xiaosong Bai	CEO & Executive Director	2.3yrs	CN¥2.55m	0.0032% CN¥ 120.2k
Ran Tao	VP & Executive Director	2.6yrs	CN¥2.76m	no data
Rong Deng	CFO & Executive Director	less than a year	no data	no data
Tingmei Fu	Independent Non-Executive Director	7.8yrs	CN¥265.08k	no data
Ruifang Jiao	Non-Executive Director	2.3yrs	no data	no data
Kejian Zhang	Independent Non-Executive Director	7.8yrs	CN¥265.08k	no data
Kin Fun Kwok	Independent Non-Executive Director	7.8yrs	CN¥265.08k	no data
Yi Feng	Chairman of China Resources Double-Crane Pharmaceutical Co.	5.3yrs	no data	no data
Wei Guo	Non-Executive Director	1.2yrs	no data	no data
Mo Han Shing	Independent Non-Executive Director	6.7yrs	CN¥265.08k	no data
Yuewei Han	Chairman	4.5yrs	CN¥2.62m	0.0048% CN¥ 180.7k
Bo Hou	Non-Executive Director	3.1yrs	no data	no data

3.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 640's board of directors are considered experienced (3.8 years average tenure).

China Resources Pharmaceutical Group Management

Management criteria checks 3/4

Key information

Recent management updates

China Resources Pharmaceutical Group Limited Announces Change of Company Secretary

China Resources Pharmaceutical Group Limited, Annual General Meeting, May 30, 2024

China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023

China Resources Pharmaceutical Group Limited Announces Executive Changes

China Resources Pharmaceutical Group Limited Announces Appointment of Non-Executive Director

Less than half of directors are independent

Recent updates

Full year 2023 earnings released: EPS: CN¥0.61 (vs CN¥0.56 in FY 2022)

Now 20% overvalued

China Resources Pharmaceutical Group Limited Announces Change of Company Secretary

China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024

Now 21% overvalued

Dividend of HK$0.17 announced

China Resources Pharmaceutical Group Limited, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: EPS: CN¥0.61 (vs CN¥0.58 in FY 2022)

China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024

China Resources Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023

First half 2023 earnings released: EPS: HK$0.48 (vs HK$0.48 in 1H 2022)

China Resources Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 31, 2023

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

China Resources Pharmaceutical Group Limited Announces Executive Changes

China Resources Pharmaceutical Group Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.16 per share at 2.2% yield

Full year 2022 earnings released: EPS: HK$0.66 (vs HK$0.60 in FY 2021)

Now 22% undervalued

China Resources Pharmaceutical Group Limited Announces Appointment of Non-Executive Director

Less than half of directors are independent

First half 2022 earnings released: EPS: HK$0.48 (vs HK$0.39 in 1H 2021)

China Resources Pharmaceutical Group Limited Announces Retirement of Mr. Tan Ying as Non-Executive Director

China Resources Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 25, 2022

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Upcoming dividend of HK$0.15 per share

China Resources Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: HK$0.60 (vs HK$0.53 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: HK$0.60 (vs HK$0.53 in FY 2020)

China Resources Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on 25 July 2022

Non-Executive Chairman Chuncheng Wang has left the company

Executive Vice Chairman of the Board Xiangming Li has left the company

Non-Executive Director Zhongliang Yu has left the company

Non-Executive Director Wei Guo has left the company

First half 2021 earnings released: EPS HK$0.39 (vs HK$0.41 in 1H 2020)

China Resources Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2020

Upcoming dividend of HK$0.12 per share

Full year 2020 earnings released: EPS HK$0.53 (vs HK$0.52 in FY 2019)

China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2020

China Resources Pharmaceutical Group Limited Announces Earnings Guidance for the Three Months Ended March 31, 2021

Full year 2020 earnings released: EPS HK$0.53 (vs HK$0.52 in FY 2019)

Non-Executive Director has left the company

Non-Executive Director has left the company

China Resources Pharmaceutical Group Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: €0.53

New 90-day high: €0.49

New 90-day high: €0.46

China Resources Pharmaceutical Group Limited (SEHK:3320) entered into a letter of intent to acquire an unknown stake in Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) from ShenZhen GTJA Investment Group Co., Ltd.

New 90-day low: €0.41

First half earnings released

New 90-day low - €0.46

First half earnings released

China Resources Pharmaceutical Group Limited to Report First Half, 2020 Results on Aug 27, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age